Elizabeth Masson-Hurlburt
Corporate Officer/Principal en CORMEDIX INC. .
Fortuna: 192 483 $ al 31/03/2024
Perfil
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CORMEDIX INC.
0.08% | 12/01/2024 | 45 397 ( 0.08% ) | 192 483 $ | 31/03/2024 |
Cargos activos de Elizabeth Masson-Hurlburt
| Empresas | Cargo | Inicio |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Elizabeth Masson-Hurlburt.
| Empresas | Cargo | Fin |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2018 |
Formación de Elizabeth Masson-Hurlburt.
| Bay Path College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
- Bolsa de valores
- Insiders
- Elizabeth Masson-Hurlburt
